期刊文献+

丹参和生脉注射液对腹腔感染并SIRS患者血清MDA和SOD的影响 被引量:4

Salvia Miltiorrhiza and Shengmai injection in the treatment of SIRS caused by abdominal infection,and the effect on oxygen free radicals
原文传递
导出
摘要 目的探讨治疗腹腔感染SIRS时加用丹参和生脉注射液对氧自由基的影响。方法将50例腹腔感染致SIRS患者随机分为对照组(常规现代医学综合治疗)及观察组(常规现代医学综合治疗加用中药丹参和生脉注射液)。动态观察体温、白细胞计数及血清丙二醛(MDA)、超氧化物歧化酶(SOD)水平。结果观察组第2,4天血MDA较对照组明显降低,而SOD水平较对照组显著升高;体温、白细胞计数下降亦快于对照组。结论在常规现代医学综合治疗基础上,加用中药丹参和生脉注射液能降低损害因子MDA,升高保护因子SOD,阻止全身炎症反应升级,对治疗SIRS有增强作用。 Objective To evaluate the influences on oxygen free radicals of SIRS due to abdominal infection treated by Salvia Miltiorrhiza and Shengmai injection. Methods Fifty patients with SIRS due to abdominal infection were divided into 2 groups:Group A,treated by combined western medicine(n=25);Group B,treated by combined western medicine plus Salvia Miltiorrhiza and Shengmai injection(n=25).Plasma malondialdehyde(MDA) and Superoxide dismutase(SOD) were measured before treatment and on day 2 and day 4 after treatment. Results The serum levels of MDA in group B decreased more rapidly than those in group A,and the serum levels of SOD in group B increased more rapidly than those in group A. Conclusions On the basis of combined western medicine treatment,addition of Salvia Miltiorrhiza and Shengmai injection has therapeutic effect on SIRS by decreasing the harmful MDA factor and increasing the defensive SOD factors,and thereby can alleviate inflammatory injury and prevent further MODS.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2011年第3期265-268,共4页 China Journal of General Surgery
基金 广东省深圳市科技和信息局课题(200803261)
关键词 全身炎症反应综合征/治疗 丹参注射液 生脉注射液 丙二醛 超氧化物歧化 Systemic Inflammatory Response/ther Salvia Miltiorrhiza Injection Shengmai Injection Malondialdehyde(MDA) Superoxide Dismutas(SOD)
  • 相关文献

参考文献16

二级参考文献104

共引文献192

同被引文献31

  • 1王伟,孙雨梅,吕德辉,刘树清.肝病性全血细胞减少56例分析[J].现代医药卫生,2006,22(14):2178-2179. 被引量:1
  • 2American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis[J].Crit Care Med,1992,20(6):864-874.
  • 3Bone R C,Balk R A,Cerra F B,et al.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis:the accp/sccm consensus conference committee.american college of chest physicians/society of critical care medicine[J].Chest,1992,101(6):1644-1655.
  • 4Christ-Crain Mirjam,Müller Beat.Procalcitonin in bacterial infections-hype,hope,more or less?[J].Swiss Med Weekly,2005,135(31-32):451-460.
  • 5Evangelos J.Giamarellos-Bourboulis,Panagiota Giannopoulou,Paraskevi Grecka,et al.Should procalcitonin be introduced in the diagnostic criteria for the systemic inflammatory response syndrome and sepsis?[J].J Crit Care,2004,19(3):152-157.
  • 6Harbarth S,Holeckova K,Froidevaux C,et al.Diagnostic value of procalcitonin,interleukin-6,and interleukin-8 in critically ill patients admitted with suspected sepsis[J].Am J Respir Crit Care Med,2001,164(3):396-402.
  • 7Johansen TE, Botto H, Cek M, et al. Critical review ofcurrent defi- nitions of urinary tract infections and proposal of an EAU/ESIU classification system[J]. Int J Antimicrob Agents, 2011, 38 : 64 70.
  • 8Wagenl.ehner FM, Licb.tenstem C, Rolfes C,et al. Diagnosis and management for urosepsis[J]. Int J Urol, 2013,20 : 963 - 970.
  • 9赵霞,王力红,马文晖,张京利,王桂珍.SIRS评分预测重症监护病房患者发生医院感染与预后的研究[J].中华医院感染学杂志,2009,19(22):3032-3034. 被引量:6
  • 10赵明,蒋鹏,汪小梅.参麦、丹参注射液治疗全身炎症反应综合征[J].江苏医药,2009,35(12):1467-1469. 被引量:11

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部